ViiV Aims To Extend HIV Drug Durations With Halozyme’s Technology
Duo Will Expand Body’s Intake Capacity For Injected Medicines
Executive Summary
ViiV Healthcare’s head of R&D tells Scrip that extending the durations of its long acting HIV treatments is possible using drug delivery technology from Halozyme Therapeutics to expand the body’s capacity to absorb injected medicines.
You may also be interested in...
ViiV Looks Ahead With Third-Gen Integrase Inhibitor From Shionogi
License deal for preclinical S-365598 continues longstanding R&D relationship between ViiV and stakeholder Shionogi, which also developed dolutegravir and cabotegravir.
GSK Promotes Ease Of Switching HIV Patients To Monthly Injection, Even During A Pandemic
Doctors and patients need to be persuaded of the benefits of switching from familiar oral therapies to Cabenuva, the once-monthly anti-HIV injection.
Deal Watch: Roche Terminates Gene Therapy Alliance, Partners In IBD With Synlogic
Roche gives back choroideremia candidate to 4D Molecular after reviewing Phase I data, partners on synthetic GI therapy with Synlogic. AbbVie opts to acquire TeneoOne under 2019 agreement.